東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁 到查詢結果 [ null ]

切換: 標籤 | MARC模式 | ISBD

FindBook

Google Book

Amazon

博客來

Complement-Induced Post-Translational Regulation of Tgf-ß Signaling on Endothelial Cells

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Complement-Induced Post-Translational Regulation of Tgf-ß Signaling on Endothelial Cells/
作者:	Liu, Kevin.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 202,
面頁冊數:	58 p
附註:	Source: Dissertations Abstracts International, Volume: 83-05, Section: B
Contained By:	Dissertations Abstracts International83-05B
標題:	Medicine -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28318851
ISBN:	9798492731151

Complement-Induced Post-Translational Regulation of Tgf-ß Signaling on Endothelial Cells
Liu, Kevin.

Complement-Induced Post-Translational Regulation of Tgf-ß Signaling on Endothelial Cells - Ann Arbor : ProQuest Dissertations & Theses, 202 - 58 p

Source: Dissertations Abstracts International, Volume: 83-05, Section: B

Thesis (M.D.)--Yale University, 2021

This item must not be sold to any third party vendors

Cardiac allograft vasculopathy (CAV) is a complex vaso-occlusive complication of heart transplantation currently identified as a major limiting factor to long-term survival in those who receive a cardiac transplant. In CAV, neointimal lesions form in graft vessels leading to ischemic complications and ultimately allograft loss. CAV is medically untreatable and affects ~50% of heart transplant patients. Endothelial cells (ECs) are a critical site where CAV lesions form, and antibodies produced by the recipient that bind to donor HLA molecules on graft endothelium (donor specific antibodies) have been identified as a key mediator in this process. Recent studies have further identified a role for antibody-mediated complement fixation, specifically in determining pro-inflammatory signaling changes induced through this process. The laboratory of my mentor, Dr. Jane-wit, studies complement-mediated signaling in ECs and has previously identified a signaling pathway implicated in CAV. In an unbiased assay to identify new components of this pathway, I unexpectedly found that TGF-s signaling molecules, canonically understood to be anti-inflammatory, were involved in complement-induced EC activation. During my thesis I defined a novel function for proteasomes as cellular chaperones to activate TGF-s signaling in response to complement activation. My thesis studies identify a pathologic role for endothelial TGF-s signaling in CAV

ISBN: 9798492731151Subjects--Topical Terms:

1092511
Medicine
Subjects--Index Terms:

Cardiac allograft vasculopath

Complement-Induced Post-Translational Regulation of Tgf-ß Signaling on Endothelial Cells
LDR:02583nmm a2200373 4500 001 2351994
005 20221111120947.5
008 241004s2021 ||||||||||||||||| ||eng d
020 $a 9798492731151
035 $a (MiAaPQ)AAI28318851
035 $a AAI28318851
040 $a MiAaPQ $c MiAaPQ
100 1 $a Liu, Kevin. $3 3691601
245 1 0 $a Complement-Induced Post-Translational Regulation of Tgf-ß Signaling on Endothelial Cells
260 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 202
300 $a 58 p
500 $a Source: Dissertations Abstracts International, Volume: 83-05, Section: B
500 $a Advisor: Jane-wit, Daniel
502 $a Thesis (M.D.)--Yale University, 2021
506 $a This item must not be sold to any third party vendors
520 $a Cardiac allograft vasculopathy (CAV) is a complex vaso-occlusive complication of heart transplantation currently identified as a major limiting factor to long-term survival in those who receive a cardiac transplant. In CAV, neointimal lesions form in graft vessels leading to ischemic complications and ultimately allograft loss. CAV is medically untreatable and affects ~50% of heart transplant patients. Endothelial cells (ECs) are a critical site where CAV lesions form, and antibodies produced by the recipient that bind to donor HLA molecules on graft endothelium (donor specific antibodies) have been identified as a key mediator in this process. Recent studies have further identified a role for antibody-mediated complement fixation, specifically in determining pro-inflammatory signaling changes induced through this process. The laboratory of my mentor, Dr. Jane-wit, studies complement-mediated signaling in ECs and has previously identified a signaling pathway implicated in CAV. In an unbiased assay to identify new components of this pathway, I unexpectedly found that TGF-s signaling molecules, canonically understood to be anti-inflammatory, were involved in complement-induced EC activation. During my thesis I defined a novel function for proteasomes as cellular chaperones to activate TGF-s signaling in response to complement activation. My thesis studies identify a pathologic role for endothelial TGF-s signaling in CAV
590 $a School code: 0265
650 $a Medicine $3 1092511
650 $a Cellular biology $3 3691603
650 $a Molecular biology $3 656078
650 $a Biophysics $v Congresses. $3 1530985
653 $a Cardiac allograft vasculopath
653 $a CA
653 $a Complement signalin
653 $a Endothelial cell
690 $a 056
690 $a 037
690 $a 078
690 $a 030
710 2 $a Yale University. $b Yale School of Medicine $3 3691602
773 0 $t Dissertations Abstracts International $g 83-05B
790 $a 026
791 $a M.D
792 $a 2021
793 $a Englis
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28318851